[ad_1]
KUALA LUMPUR (December 7): MY EG Services Bhd (MYEG) announced today that it has established a cooperation with Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Zhifei) to obtain Malaysia’s Halal certification for COVID-19 vaccine from the Chinese biopharmaceutical company and exclusively distribute the vaccine in Malaysia for a period of 3 years.
In a statement today, MYEG said that the two companies signed a Memorandum of Understanding, agreeing to cooperate in conducting Phase 3 clinical trials of the Zhifei vaccine in Malaysia and achieving compliance with Halal status requirements to ensure the Halal certification from the Department of Islamic Development of Malaysia. (JAKIM).
MYEG said that the start of the phase 3 trial will make Zhifei’s vaccine one of the first to undergo this end-stage trial in Malaysia under the Ministry of Health.
Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co., Ltd., listed on the Shenzhen Stock Exchange and engaged in biological products industry since 2002, mainly the production of vaccines for human use. Currently, Zhifei is one of five Chinese companies conducting phase 3 clinical trials of its COVID-19 vaccines in various parts of the world.
Upon successful completion of Phase 3 trials, MYEG will be the sole distributor of the vaccine in Malaysia.
Since November 1, 2020, MYEG has been appointed by the Malaysian Ministry of Health to develop and operate the MySafeTravel digital health pass system to facilitate inbound travelers’ compliance with mandatory COVID-19 testing and quarantine requirements. .
In addition, MYEG also operates a single portal for COVID-19 detection of workers in the country, which includes a collaboration to share data with the Department of Labor of Peninsular Malaysia.
MYEG was last traded at RM1.81, valued at RM6.61 billion.
[ad_2]
